company background image
0MH6 logo

Ipsen LSE:0MH6 Stock Report

Last Price

€108.04

Market Cap

€8.9b

7D

-1.1%

1Y

-9.7%

Updated

07 Sep, 2024

Data

Company Financials +

0MH6 Stock Overview

Operates as a biopharmaceutical company worldwide.

0MH6 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth2/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Ipsen S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price€108.04
52 Week High€130.70
52 Week Low€99.50
Beta0.60
11 Month Change6.33%
3 Month Change-12.38%
1 Year Change-9.73%
33 Year Change35.47%
5 Year Change18.66%
Change since IPO188.26%

Recent News & Updates

Recent updates

Shareholder Returns

0MH6GB PharmaceuticalsGB Market
7D-1.1%-4.2%-1.6%
1Y-9.7%15.9%9.0%

Return vs Industry: 0MH6 underperformed the UK Pharmaceuticals industry which returned 15.9% over the past year.

Return vs Market: 0MH6 underperformed the UK Market which returned 9% over the past year.

Price Volatility

Is 0MH6's price volatile compared to industry and market?
0MH6 volatility
0MH6 Average Weekly Movement3.1%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement4.6%
10% most volatile stocks in GB Market9.3%
10% least volatile stocks in GB Market2.6%

Stable Share Price: 0MH6 has not had significant price volatility in the past 3 months.

Volatility Over Time: 0MH6's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19295,325David Loewwww.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
0MH6 fundamental statistics
Market cap€8.92b
Earnings (TTM)€663.90m
Revenue (TTM)€3.44b

13.4x

P/E Ratio

2.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0MH6 income statement (TTM)
Revenue€3.44b
Cost of Revenue€618.00m
Gross Profit€2.82b
Other Expenses€2.15b
Earnings€663.90m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)8.04
Gross Margin82.01%
Net Profit Margin19.33%
Debt/Equity Ratio9.6%

How did 0MH6 perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

15%

Payout Ratio